PIPELINE
PIPELINE
Candidate | Imaging Modality | Anatomy | Proof of Concept | Formula Development | Approvals* | Test Market | Commercial Launch |
---|---|---|---|---|---|---|---|
SmoothX 2.0% | CT |
|
CND: 2021
US: 2022 EU: 2023 |
CND: 2021/2022
US: 2022 EU: 2023 |
CND: 2022
US: 2023 EU: 2023 |
||
MultiX Thick | Fluoroscopy |
|
CND: 2021
US: 2022 EU: 2023 |
CND: 2021/2022
US: 2022 EU: 2023 |
CND: 2022
US: 2023 EU: 2023 |
||
MultiX Thin | Fluoroscopy |
|
CND: 2021
US: 2022 EU: 2023 |
CND: 2021/2022
US: 2022 EU: 2023 |
CND: 2022
US: 2023 EU: 2023 |
||
HDX | Fluoroscopy |
|
CND: 2021
US: 2022 EU: 2023 |
CND: 2021/2022
US: 2022 EU: 2023 |
CND: 2022
US: 2023 EU: 2023 |
||
LDX | Fluoroscopy |
|
CND: 2021
US: 2022 EU: 2023 |
CND: 2021/2022
US: 2022 EU: 2023 |
CND: 2022
US: 2023 EU: 2023 |
||
VY-101 | MRI |
|
Neutral |
1H/2022 |
1H/2023 |
2H/2023 |
1H/2024 |
VY-102 (a,b,c,d) | Fluoroscopy |
|
Dysphagia |
1H/2022 |
1H/2023 |
2H/2023 |
1H/2024 |
IoXp (Iopamidol) | Fluoro / CT |
|
2H/2022 |
1H/2024 |
2H/2024 |
1H/2025 |
|
IoXh (Iohexol) | Fluoro / CT |
|
2H/2022 |
1H/2024 |
2H/2024 |
1H/2025 |
|
VY-103 | Fluoro / CT |
|
ESI |
2H/2022 |
1H/2024 |
2H/2024 |
1H/2025 |